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Introduction: The purpose of this study was to document the efficacy and tolerability of the 
new fixed-combination (FC) brinzolamide 1%/timolol 0.5% as used in daily practice throughout 
Germany.
Methods: An open-label, multicenter, observational study of patients was performed that 
evaluated the transition from prior medication to brinzolamide/timolol FC for the reduction of 
intraocular pressure (IOP). Ophthalmologists measured IOP at baseline and 4–6 weeks 
after transition and assessed their satisfaction with brinzolamide/timolol FC. Patients assessed 
the   tolerability of both their previous and new regimens, judged their satisfaction with 
  brinzolamide/timolol, and reported their preference between their previous and new regimens. 
Patients transitioning from other FC products to brinzolamide/timolol FC were analyzed 
separately.
Results: Data from 14,025 patients from 1161 centers were analyzed. Four to 6 weeks after 
transition to brinzolamide/timolol, patients experienced a mean IOP decrease of 3.9 ± 4.3 mm Hg 
(p , 0.0001). All of the predefined patient subgroups (grouped by previous therapy) demon-
strated a significant mean IOP reduction following transition to brinzolamide/timolol 
(p , 0.0001). Patients judged brinzolamide/timolol tolerability more positively than they did 
their previous therapies (87.2% vs 53.7% favorable assessments) and reported a high   satisfaction 
rating with brinzolamide/timolol (93.4%). Brinzolamide/timolol was preferred over previous 
therapy at a ratio of almost 9:1. Patients who transitioned from dorzolamide/timolol to 
  brinzolamide/timolol (n = 2937) demonstrated a significant decrease in mean IOP (p , 0.0001), 
rated brinzolamide/timolol more tolerable than dorzolamide/timolol (88.9% vs 28.9%), and 
preferred brinzolamide/timolol at a ratio of more than 9:1. Patients who transitioned from 
brimonidine/timolol (n = 209) demonstrated a significant decrease in mean IOP (p , 0.0001), 
rated   brinzolamide/timolol more tolerable (86.5% vs 32.1%), and preferred brinzolamide/timolol 
at a ratio of 11.5:1.
Conclusions: The FC brinzolamide 1%/timolol 0.5% produced better IOP control than 
all previous therapies analyzed and demonstrated favorable tolerability and a high satisfac-
tion rating, resulting in a strong patient preference for brinzolamide/timolol over previous 
therapies.
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Introduction
Several different classes of drugs are available for the reduction of elevated intraocular 
pressure (IOP) associated with open-angle glaucoma or ocular hypertension, including 
β-blockers, carbonic anhydrase inhibitors (CAIs), prostaglandin analogs (PGAs), and 
α-2 agonists. Many patients, however, experience insufficient IOP reduction with Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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single-agent therapy; in these cases, patients will transition 
to a two-drug regimen, which can be two individual agents 
or a fixed-combination (FC) product.
All of the currently available FC products combine the 
β-blocker timolol with another drug from a different class 
of IOP-lowering agents. The first FC product made available 
in 1998 combined the CAI dorzolamide 2% with timolol 
0.5% (Cosopt®, Merck & Co., Inc., Whitehouse Station, 
NJ, USA). Since then, other FC products have reached the 
market, including the PGA-containing products latanoprost 
0.005%/timolol 0.5% (Xalacom®, Pfizer Inc., New York, 
NY, USA), travoprost 0.004%/timolol 0.5% (DuoTrav®, 
Alcon Laboratories, Inc., Fort Worth, TX, USA), bimatoprost 
0.03%/timolol 0.5% (Ganfort®, Allergan Inc., Irvine, CA, USA), 
and the α-2 agonist-containing brimonidine 0.2%/timolol 
0.5% (Combigan®, Allergan Inc.). Most recently, FC brin-
zolamide 1%/timolol 0.5% (Azarga®, Alcon Pharma GmbH, 
Puurs, Belgium) received regulatory approval by the European 
Medicines Agency in November 2008 for the treatment of 
patients for whom monotherapy provides insufficient IOP 
reduction.1
As a result of this approval, the German Medicines Act 
(AMG) requires that the pharmaceutical marketing authoriza-
tion holder (Alcon Pharma) gathers data related to the use 
of Azarga® after its introduction to the market.2 A prospec-
tive, observational trial, in which the medication is prescribed 
in a clinical practice, can provide data from the actual use of 
this product. Thus, the goal of the current noninterventional 
study was to document the efficacy and tolerability of the 
new FC brinzolamide 1%/timolol 0.5% to comply with this 
requirement by the AMG.
Methods
This was an open-label, multicenter, observational study of 
patients who were treated with brinzolamide/timolol FC for 
the reduction of IOP. Centers and patients were located 
throughout Germany to ensure adequate and representative 
samples for the subgroup analyses. All therapy decisions, 
including the decision to transition to brinzolamide/timolol, 
were made solely at the treating ophthalmologist’s discretion. 
Inclusion and exclusion criteria were in accordance with the 
Azarga® Summary of Product Characteristics.1 All patients 
meeting these criteria who were transitioned to brinzolamide/
timolol from January 2010 to July 2010 were included. 
All patients must have had IOP data at both the baseline visit 
and the Week 4–6 visit.
The following data were collected by the ophthalmolo-
gists using standardized data sheets: patient initials, gender, 
age, glaucoma type, explanatory notes for the transition to 
brinzolamide/timolol, baseline IOP, and IOP at the 
Week 4–6 visit. IOP was measured at each site using the 
method that was standard for that clinical practice. Patients 
assessed both the tolerability of their previous IOP-lowering 
regimen and their brinzolamide/timolol regimen using the 
descriptors “very good”, “good”, “moderate”, and “not sat-
isfactory”, and they reported their preference between their 
previous and new regimens. Both patients and ophthalmolo-
gists assessed their satisfaction with brinzolamide/timolol 
using the descriptors “excellent”, “very good”, “good”, “satis-
factory”, and “not satisfactory”.
A predefined subgroup analysis based on previous and 
new therapies was conducted in which change in IOP from 
the baseline visit to the Week 4–6 visit was calculated for 
patients who had been taking one of the following IOP- 
lowering regimens and then transitioned to brinzolamide/
timolol FC: no previous therapy, timolol 0.5%, brinzolamide 1%, 
dorzolamide 2%, FC dorzolamide 2%/timolol 0.5%, PGA 
(bimatoprost 0.03%, latanoprost 0.005%, tafluprost 0.0015%, 
or travoprost 0.004%), FC PGA/timolol 0.5%, FC brimonidine 
0.2%/timolol 0.5%, brinzolamide 1% + timolol 0.5%, dorzo-
lamide 2% + timolol 0.5%, or PGA + timolol 0.5%. Change 
in IOP from the baseline visit to the Week 4–6 visit was also 
assessed for patients who had been taking one of the following 
combination IOP-lowering regimens and then transitioned to 
PGA + brinzolamide/timolol: PGA + brinzolamide, PGA + 
dorzolamide, or PGA + dorzolamide/timolol.
Statistical analysis was performed by the contract 
research organization MedPharmTec® Services (Munich, 
Germany). Descriptive statistics were analyzed using fre-
quency, median, mean, standard deviation, range, and 
quartile, depending on the parameter. IOP was analyzed as 
patient individual deviation analysis. The study was reported 
to the German Federal Institute for Drug and Medical Devices 
(BfArM).
Results
Data from 14,025 patients from 1161 centers were analyzed 
in the study (n = 14,021 evaluable patients). The median age 
of these patients was 69 years and 58% were female. Most 
patients were diagnosed with either primary open-angle 
glaucoma (80.1%) or ocular hypertension (8.1%) (Table 1). 
The reasons for the transition in therapy to brinzolamide/
timolol FC varied, with some patients having more than one 
reason, but the large majority were transitioned due to either 
an insufficient reduction in IOP with previous therapy 
(54.0%) or intolerance to previous therapy (28.9%).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Efficacy
The mean IOP at baseline for these patients was 20.7 ± 5.0 mm 
Hg. After 4–6 weeks on brinzolamide/timolol, these patients 
had a mean IOP of 16.8 ± 3.6 mm Hg and a mean IOP decrease 
of 3.9 ± 4.3 mm Hg (18.8%) from baseline (p , 0.0001). 
A predefined prospective subgroup analysis of patients using 
one of 14 different IOP-lowering regimens comprised 10,497 
patients, representing 75% of the total patient population 
(Table 2). Most of the remaining 25% of patients not 
included in this analysis had been treated with α-2 agonists, 
parasympathomimetics, β-blockers other than timolol, or 
other combinations (fixed or unfixed). All subgroups demon-
strated a reduction of mean IOP after transitioning to brinzo-
lamide/timolol, whether alone or in combination with a PGA. 
  Figure 1 illustrates the magnitude of the change in mean IOP 
from baseline to the Week 4–6 visit, ranging from 1.9 mm Hg 
mean reduction for those patients previously on a PGA + 
  dorzolamide/timolol who transitioned to a PGA + brinzol-
amide/ timolol to a 4.8 mm Hg reduction for patients previ-
ously on timolol alone who transitioned to brinzolamide/
timolol FC. Less than 4% of patients were given brinzolamide/
timolol FC as an off-label, first-line therapy. As would be 
expected of an untreated population, they experienced the 
largest mean reduction in IOP (9.0 mm Hg; 35%) of all sub-
groups. All of the patient subgroups analyzed had a statisti-
cally significant reduction in IOP following transition to 
brinzolamide/timolol (p , 0.0001).
Tolerability
When asked about the tolerability of brinzolamide/timolol, 
87.2% of patients judged it positively, with 35.7% reporting 
it to be very good and 51.5% reporting it to be good. Compared 
with patients’ evaluation of their previous therapy, this repre-
sented an increase of positive tolerability assessments of 33.5% 
(53.7% very good or good with previous therapy vs 87.2% 
very good or good with brinzolamide/timolol therapy).
satisfaction
Overall satisfaction with brinzolamide/timolol was similar 
between patient and investigator assessments, with 87.5% 
Table 1 Patient demographics (n = 14,025)
Demographic Percentage   
of patients
gender
Male 42.0
Female 58.0
Diagnosis
Primary open-angle glaucoma 80.1
Ocular hypertension 8.1
Pseudoexfoliative glaucoma 3.7
Other 8.1
Reasons for transition to brinzolamide/timolol 
(multiple answers may apply)
Insufficient intraocular pressure lowering under 
previous therapy
54.0
intolerance to previous therapy 28.9
Progressive disease 15.8
Cost reduction 14.7
Vascular aspects 8.7
Insufficient patient compliance with previous therapy 7.6
Table 2 Efficacy of study treatment for predefined patient subgroups (n = 10,497)
Previous therapy New therapy n Mean IOP at  
baseline (mm Hg)
Mean IOP 4–6 weeks 
after transition (mm Hg)
nonea Brinzolamide 1%/timolol 0.5% 435 25.7 ± 6.3 16.7 ± 3.5
Timolol 0.5% Brinzolamide 1%/timolol 0.5% 2446 21.9 ± 3.9 17.1 ± 3.0
Brinzolamide 1% Brinzolamide 1%/timolol 0.5% 933 20.9 ± 4.1 16.4 ± 3.2
Dorzolamide 2% Brinzolamide 1%/timolol 0.5% 458 21.3 ± 4.7 16.8 ± 3.7
Prostaglandin analog (PgA)b Brinzolamide 1%/timolol 0.5% 1015 20.7 ± 4.3 16.6 ± 3.2
Dorzolamide 2%/timolol 0.5% Brinzolamide 1%/timolol 0.5% 2937 18.5 ± 4.1 16.5 ± 3.2
PGA/timolol 0.5%c Brinzolamide 1%/timolol 0.5% 611 20.8 ± 4.6 17.8 ± 4.2
Brimonidine 0.2%/timolol 0.5% Brinzolamide 1%/timolol 0.5% 209 20.1 ± 4.0 17.4 ± 3.3
Brinzolamide 1% + timolol 0.5% Brinzolamide 1%/timolol 0.5% 252 18.4 ± 3.4 16.6 ± 2.9
Dorzolamide 2% + timolol 0.5% Brinzolamide 1%/timolol 0.5% 73 18.7 ± 3.5 16.5 ± 2.9
PgA + timolol 0.5% Brinzolamide 1%/timolol 0.5% 92 20.5 ± 3.9 17.8 ± 3.1
PgA + brinzolamide 1% Brinzolamide 1%/timolol 0.5% + PgA 150 20.9 ± 4.8 16.3 ± 3.6
PgA + dorzolamide 2% Brinzolamide 1%/timolol 0.5% + PgA 63 20.9 ± 7.4 16.4 ± 5.3
PgA + dorzolamide 2%/timolol 0.5% Brinzolamide 1%/timolol 0.5% + PgA 823 18.3 ± 5.0 16.4 ± 3.9
Notes: aBrinzolamide/timolol is not indicated for the first-line treatment of elevated IOP; thus, this subgroup of patients was treated off-label; bPgA = bimatoprost 0.03%, 
latanoprost 0.005%, tafluprost 0.0015%, or travoprost 0.004%; cFixed-combination PGA/timolol = latanoprost 0.005%/timolol 0.5%, travoprost 0.004%/timolol 0.5%, and 
bimatoprost 0.03%/timolol 0.5%.
Abbreviations: iOP, intraocular pressure; PgA, prostaglandin analog.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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of 14,025 investigators and 88.8% of 13,837 patients rating 
this regimen favorably (Figure 2). Investigators were more 
highly satisfied than patients with this regimen (60.9% vs 
53.5% excellent or very good).
Patient preference
Therapy preference data were evaluable for 13,346 patients. 
Of these patients, 75.9% preferred brinzolamide/timolol FC, 
whereas 8.6% favored their previous therapy, and 15.5% had 
no preference. Thus, of the patients with a therapy preference, 
brinzolamide/timolol was preferred over previous therapy at 
a ratio of almost 9:1.
Comparison of non-PgA FC products 
with brinzolamide/timolol FC
The most common previous therapy in this study was 
  dorzolamide/timolol (N = 2937), representing over 20% of 
the total population. The majority of this subgroup of patients 
(56.7%) transitioned to brinzolamide/timolol because of 
intolerance to dorzolamide/timolol (as judged by the treating 
physician; Table 3), a proportion that was substantially higher 
than intolerance to previous therapy cited in the overall 
population (28.9%). When these patients were transitioned 
from dorzolamide/timolol to brinzolamide/timolol, mean 
IOP decreased by 10.8% from 18.5 ± 4.1 mm Hg to 
16.5 ± 3.2 mm Hg (p , 0.0001). These patients rated the 
tolerability of brinzolamide/timolol substantially higher than 
they did dorzolamide/timolol, with the positive responses of 
very good and good increasing from 29.2% with dorzolamide/
timolol to 88.9% with brinzolamide/timolol (  Figure 3). 
Similar to the overall population, patients in this subgroup 
preferred brinzolamide/timolol over dorzolamide/timolol at 
a ratio of more than 9:1 (82.0% vs 8.8%; Figure 4). For the 
209 patients who transitioned from FC brimonidine/timolol 
to brinzolamide/timolol, a reduction in mean IOP of 13.4% 
was observed (20.1 ± 4.0 mm Hg vs 17.4 ± 3.3 mm Hg; 
p , 0.0001). More patients rated brinzolamide/timolol favor-
ably than they did brimonidine/timolol (86.5% vs 32.1%; 
Figure 5), and these patients preferred brinzolamide/timolol 
over brimonidine/timolol at a ratio of 11.5:1 (75.8% vs 6.6%; 
Figure 6).
Comparison of PgA FC products  
to brinzolamide/timolol FC
A total of 611 patients transitioned from FC PGA/timolol 
to brinzolamide/timolol, achieving a reduction in mean 
IOP of 14.4% (20.8 ± 4.6 mm Hg vs 17.8 ± 4.2 mm Hg; 
p , 0.0001). More patients rated the tolerability of 
brinzolamide/timolol as very good or good than they did 
PGA/timolol (81.3% vs 45.0%), and 5.3-fold more of these 
patients preferred brinzolamide/timolol than they did PGA/
timolol (68.9% vs 13.1%).
Discussion
In this large, noninterventional study examining the use of 
brinzolamide/timolol, patients were transitioned from their 
previous therapy to this product at their ophthalmologist’s 
discretion, most frequently because of a failure to reach target 
IOP or because of intolerance to previous therapy. The transi-
tion to brinzolamide/timolol produced a 3.9 mm Hg (18.8%) 
improvement in IOP after 4–6 weeks of use, for a mean IOP 
with brinzolamide/timolol of 16.8 ± 3.6 mm Hg. A statisti-
cally significant reduction in mean IOP (p , 0.0001) was 
observed across all predefined subgroups, suggesting that 
brinzolamide/timolol was an effective second-line regimen, 
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Figure 1B Change in mean intraocular pressure from baseline to 4–6 weeks after 
transition to brinzolamide/timolol + a prostaglandin analog in patient subgroups with 
various previous therapies.
Abbreviations: iOP, intraocular pressure; PgA, prostaglandin analog.
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Figure 1A Change in mean iOP from baseline to 4–6 weeks after transition to 
brinzolamide/timolol in patient subgroups with various previous therapies.
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Figure 2 Patient- and investigator-assessed satisfaction with brinzolamide/timolol after 4–6 weeks of therapy.
Table  3  Reasons  for  transition  from  dorzolamide/timolol  to 
brinzolamide/timolol (n = 2937)
Reasons for transition  
to brinzolamide/timolol  
(multiple answers may apply)
Percentage   
of patients
intolerance to previous therapy 56.7
Cost reduction 27.7
Insufficient intraocular pressure lowering 
under previous therapy
23.7
Insufficient patient compliance with 
previous therapy
8.6
Progressive disease 6.6
Vascular aspects 5.2
producing additional reductions in IOP regardless of the type 
of previous therapy used.
A possible limitation of this type of noninterventional 
study is the lack of standardization of IOP measurement. 
However, a recent paper reported that three distinct methods 
of IOP measurement (dynamic contour, ocular response 
analyzer, and Goldmann applanation tonometry) produced 
clinically acceptable measurement repeatability and repro-
ducibility, including acceptably low levels of interobserver 
variability.3 Thus, it appears likely that the lack of a stan-
dardized approach to IOP measurement had little effect on 
IOP outcome measures. In any case, the results reflect the 
r  eal-world data used by ophthalmologists to make treatment 
decisions.
The tolerability of brinzolamide/timolol was overwhelm-
ingly positive, with nearly 90% of patients judging its toler-
ability to be either good or very good. This was in contrast 
with previous therapy, for which just over half of the patients 
rated their previous IOP-lowering medication positively. 
Although this was not surprising, given that nearly 30% 
of patients transitioned to brinzolamide/timolol due to 
intolerance to their previous therapy, it indicated that this 
FC product is a favorable choice in these circumstances. 
  Supporting this conclusion is the high patient satisfaction 
with brinzolamide/timolol reported in the current study 
(93.4% satisfied) and the good safety profile of brinzolamide/
timolol, producing ocular adverse events such as blurred 
vision, eye pain or irritation, and foreign body sensation 
in ,10% of patients.1 The fact that patients reported a prefer-
ence for their new regimen over their previous regimen at a 
ratio of nearly 9:1 further substantiates this claim. However, 
it should be noted that because of the limited duration of 
brinzolamide/timolol therapy prior to patient assessment 
(4–6 weeks), any long-term side effects would not have yet 
developed, resulting in the possibility of an artificially favor-
able tolerability profile of brinzolamide/timolol compared 
with previous therapy.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The results of this study should be considered in light of 
two phenomena: the Hawthorne effect and regression to the 
mean. The Hawthorne effect describes a phenomenon in 
which study results show improvement simply because a 
measure is being assessed rather than because an intervention 
is having a true positive effect.4 In the current study, it is 
feasible that changing a patient’s medication may have 
  produced improved outcomes regardless of which medication 
was prescribed. Although it is plausible that this may have 
impacted the patient assessment results of tolerability and 
drug preference, it is less likely to have impacted an objective 
measure like IOP. The second phenomenon of regression to 
the mean suggests that the favorable results of brinzolamide/
timolol may lessen over time, particularly since the follow-up 
was short. To determine whether this is indeed the case, this 
medication would have to be examined in a long-term study 
(ie, having at least 1 year of follow-up).
This observational study also provided an opportunity to 
compare the real-world use of two similar products, the CAI-
containing FC dorzolamide/timolol and brinzolamide/
timolol. Nearly 3000 enrolled patients transitioned from the 
dorzolamide combination product to brinzolamide/timolol, 
with more than half of them doing so because of their intoler-
ance to their previous therapy, according to their treating 
physician. This was substantially higher than the 28.9% of 
patients from the total study population who made a change 
due to intolerance. In fact, dorzolamide/timolol has a chal-
lenging safety profile, producing dysgeusia and ocular burn-
ing and/or stinging in up to 30% of patients.5 In the current 
study, less than one-third of patients taking dorzolamide/
timolol rated its tolerability positively, and more than one-
quarter judged it to be unsatisfactory. After transitioning to 
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Figure 4 Patient preference between dorzolamide/timolol and brinzolamide/timolol 
4–6 weeks after transition to brinzolamide/timolol (n = 2819).
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Figure 3 Patient-reported tolerability of dorzolamide/timolol vs brinzolamide/timolol (n = 2729).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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brinzolamide/timolol, the vast majority of these patients rated 
the tolerability of their new regimen positively, indicating 
that they found brinzolamide/timolol to be more comfort-
able than dorzolamide/timolol. This hypothesis was   supported 
by results from a clinical trial designed to directly compare 
the comfort of these two products.6 In this randomized, 
double-masked study, the brinzolamide/timolol group had a 
significantly lower mean ocular discomfort score (p = 0.0003) 
and a greater incidence of patients reporting no ocular dis-
comfort after 1 week of therapy than the dorzolamide/timolol 
group (49% vs 15%, p = 0.0004). The apparent increase in 
comfort of brinzolamide/timolol therapy may be due to its 
near physiologic pH of 7.2;6 in contrast, dorzolamide/timolol 
has an acidic pH of 5.65.5 Again, patient preference data 
from the current study support the favorable tolerability of 
brinzolamide/timolol, which was preferred more than 9:1 
over dorzolamide/timolol.
Despite the similar mechanisms of action of these two 
CAI-containing FC treatments, a modest but statistically 
significant reduction in IOP was observed in the current study 
on transitioning to brinzolamide/timolol therapy. Interestingly, 
a randomized noninferiority trial of 437 patients comparing 
these two combinations reported similar IOP reductions with 
both products.7 However, the reduction in IOP from the cur-
rent study can potentially be explained if patients had better 
adherence to the brinzolamide/timolol regimen. It is reason-
able to suggest that patients may be more inclined to comply 
with an agent with a favorable tolerability profile than with 
one that causes discomfort. In fact, a positive relationship 
between tolerability and patient adherence has been sug-
gested in several glaucoma publications.8–11 This hypothesis, 
however, remains to be tested in a rigorous manner.
Brinzolamide/timolol also compared favorably against 
other FC products, specifically PGA/timolol products and 
α-2 agonist-containing brimonidine/timolol. Despite the 
relatively small number of patients included in these subsets 
(n = 611 and n = 209, respectively), both groups demon-
strated significant improvements in IOP after transition to 
brinzolamide/timolol, and most patients in both groups found 
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Figure 5 Patient-reported tolerability of brimonidine/timolol vs brinzolamide/timolol (n = 209).
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Figure 6 Patient preference between brimonidine/timolol and brinzolamide/timolol 
4–6 weeks after transition to brinzolamide/timolol (n = 209).Clinical Ophthalmology
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brinzolamide/timolol to be more tolerable and preferred over 
their previous therapy. This preference imbalance was par-
ticularly evident in the brimonidine/timolol group, where 
patient preference was 11.5:1 for brinzolamide/timolol over 
previous therapy.
Although the nonrandomized, open-label nature of a 
noninterventional study limits the type of conclusions that 
can be drawn from its results, it does have some advantages 
over data obtained from a clinical trial. That is, an observa-
tional trial usually involves a much larger patient population, 
making it more likely to obtain an accurate picture of the 
true effect of a drug on its patient population. Furthermore, 
unlike a highly regulated clinical trial with a restricted patient 
population and strictly defined usage, a noninterventional 
study can accurately reveal the efficacy and safety of a drug 
as it is truly used in clinical practice.
In the real-world setting of the current study, brinzo-
lamide 1%/timolol 0.5% FC produced better IOP control 
than all previous therapies analyzed and demonstrated 
favorable tolerability, resulting in a strong patient preference 
for   brinzolamide/timolol over other therapies. These data, 
collected from the daily practice of more than 1100 ophthal-
mologists across Germany, demonstrated that brinzolamide/
timolol was an effective second-line choice for the treatment 
of patients transitioning to a new IOP-lowering regimen.
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